High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.
about
Burkitt lymphoma in adolescents and young adults: management challenges.Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trialPrimary Gastric Burkitt's Lymphoma.Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice.Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma.Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient.Complete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report.Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma.Rituximab in the management of acute lymphoblastic leukemia.Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.Relapsed/refractory Burkitt lymphoma and HIV infection.
P2860
Q30238965-8976BB02-A41D-4EED-A518-34CBE2C6D5B9Q30240133-8128114B-FD8D-4788-B230-BEA4E2D21DADQ33441858-6C01125B-FD4B-4DF7-8378-60DE4F89111CQ34344942-9C194F40-9F16-4CA5-9B18-FE5DC359FE01Q34737471-E83D1456-1883-4BD0-8FCE-0B93E0953D08Q34760470-F372C31B-2FDB-4850-B313-78C25C7C14D0Q35429833-35621E87-9D1A-4D37-8BDC-0A8D324262DDQ37718297-0F5AEB10-1129-4149-B676-656F2AC1DD1FQ40461529-D4682AF7-169D-4BA7-A64D-066ADE7CA0A4Q41663533-C4113698-4962-40C7-8C37-40510A7BDE7DQ41914154-DB1AE1F5-8A49-4CA6-8EC3-7165092BA466Q42526609-F08F2B2D-C596-4375-BF2B-7A19AD3A408EQ42861612-0FAEACBE-ED8E-445E-87B4-395C7471C18AQ47196522-2BAEE17A-CC6C-4341-A74B-353C346CF639Q47361098-0F249784-266D-4AF5-9C36-2E8D2A02E2F0Q47562321-DF5D7E85-CAFD-4F66-A85E-DD7F7303149C
P2860
High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High cure rates in Burkitt lym ...... ituximab-chemotherapy program.
@en
High cure rates in Burkitt lym ...... ituximab-chemotherapy program.
@nl
type
label
High cure rates in Burkitt lym ...... ituximab-chemotherapy program.
@en
High cure rates in Burkitt lym ...... ituximab-chemotherapy program.
@nl
prefLabel
High cure rates in Burkitt lym ...... ituximab-chemotherapy program.
@en
High cure rates in Burkitt lym ...... ituximab-chemotherapy program.
@nl
P2093
P2860
P50
P921
P1433
P1476
High cure rates in Burkitt lym ...... rituximab-chemotherapy program
@en
P2093
Alessandro Levis
Alessandro Rambaldi
Anna Maria Scattolin
Chiara Pagani
Claudio Romani
Elena Oldani
Elisabetta Terruzzi
Enrico Maria Pogliani
Eros Di Bona
Federica Delaini
P2860
P304
P356
10.3324/HAEMATOL.2013.086827
P577
2013-06-10T00:00:00Z